Loomis Sayles & Co. L P Acquires 62,969 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Loomis Sayles & Co. L P increased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 59.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 169,621 shares of the specialty pharmaceutical company’s stock after buying an additional 62,969 shares during the period. Loomis Sayles & Co. L P’s holdings in Jazz Pharmaceuticals were worth $20,889,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of JAZZ. CIBC Asset Management Inc raised its position in shares of Jazz Pharmaceuticals by 5.2% in the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock worth $243,000 after acquiring an additional 97 shares in the last quarter. UMB Bank n.a. grew its stake in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 129 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 130 shares in the last quarter. Waterfront Wealth Inc. raised its holdings in Jazz Pharmaceuticals by 1.4% in the fourth quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company’s stock worth $1,191,000 after purchasing an additional 137 shares in the last quarter. Finally, Ellsworth Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 0.4% during the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock valued at $4,675,000 after buying an additional 149 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 2.8 %

JAZZ stock opened at $122.92 on Friday. The company has a market capitalization of $7.47 billion, a P/E ratio of 17.31, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06. The firm’s fifty day simple moving average is $132.30 and its 200-day simple moving average is $122.43. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Analysts Set New Price Targets

Several research analysts recently commented on JAZZ shares. Barclays reiterated an “overweight” rating and set a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. Piper Sandler restated an “overweight” rating and set a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Finally, Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $187.71.

Insider Activity at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,140 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the sale, the chief accounting officer now directly owns 7,012 shares of the company’s stock, valued at $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the transaction, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock worth $4,022,825 over the last three months. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.